RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Clinical trials for RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK trials appear
Sign up with your email to follow new studies for RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy drug may save eyes from aggressive skin cancer
Disease control OngoingThis study tests whether the immunotherapy drug pembrolizumab can shrink or control advanced or recurrent skin cancer near the eye. About 22 adults with this condition will receive the drug. The goal is to see if the cancer responds and if the eye can be saved from surgery.
Matched conditions: RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
Disease control OngoingThis phase I trial is testing whether a combination of three treatments — an experimental drug called elimusertib, precise radiation therapy, and the immunotherapy pembrolizumab — can shrink or stabilize recurrent head and neck cancer that cannot be removed by surgery. The study …
Matched conditions: RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Immunotherapy before surgery shows promise for head and neck cancer
Disease control OngoingThis phase II trial is testing whether giving the immunotherapy drug cemiplimab before surgery can help shrink tumors in people with stage II to IV head and neck skin cancer that can be removed. The study enrolled 44 participants and aims to see how many respond to the drug. If i…
Matched conditions: RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC